Answers are grounded in this paper and cite their sources.
These results offer preclinical evidence for myricetin as a potential chemopreventive and therapeutic agent for precision medicine tailored to prostate cancer patients characterized by concomitant elevated expression of PIM1 and CXCR4.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: